MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why CRMD Stock dropped -6.83% Today — RQD Quant Desk Flash
$7.64 -6.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.53
CorMedix Inc. (CRMD) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $595.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.53 (-1.42%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 55.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRMD)Realized 20D OHLCV Swing Band: ±11.4%
Deterministic 5-Pillar Attribution (62/100 Composite)
🔍 WHY CRMD SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 55.4% FCF Margin ($172.8M FCF) & 88.5% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (24% of score)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$7.38-1.6% Next Q
54
Q2 (-2Q)Grade C$7.26+8.1% Next Q
57
Q3 (-1Q)Grade C$7.85-2.7% Next Q
59
CurrentGrade C$7.64+0.7% Hist 90D α
62
Trajectory: C- (54) → C (62)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the CRMD Bull Thesis Could Fail
Even with a 62/100 (C) score, CRMD faces multiple-compression risk if 3.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 86.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($7.80) or 200D SMA ($7.67) invalidates the momentum regime and cuts Target Base ($7.78) toward Bear Floor ($6.07).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CRMD Stock dropped -6.83% Today — RQD Quant Desk Flash
CorMedix Inc. (CRMD) dropped -6.83% to $7.64, trading at 27% of its 52-week range ($5.63 – $13.02). Solid 89% profit margin (46% return on capital), mixed timing at 4x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 27% of its 52-week range ($5.63 – $13.02) with RSI-14 at 25.3 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.4% around $7.64 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 88.5% gross margin and $172.8M annual free cash flow.
Live CRMD Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (CRMD Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.66%▼ DESCENDING CHANNEL
2026-10-30O $7.68H $7.68L $5.63C $7.64VOL 7.01M
RES: $8.84SUP: $6.38SMA50: $7.80SMA200: $7.67
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-15.0%/yr Implied 5Y Growth
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CRMD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CRMD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRMD)
Health Care Rank #171 of 1016
⚔️ CLYM vs CRMD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CRMD vs. CLYM, IRWD, ACRS, NVCT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, CorMedix Inc. (CRMD) ranks #171 by composite RQD confidence (62/100, grade C) and #422 by equity capitalization ($595.5M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with CRMD at 62/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRMD
ACTIVE
CorMedix Inc. | C | 62/100 | 3.7x | 88.5% | 45.5% | -6.83% | $595.5M | Benchmark Subject |
| CLYM Climb Bio Inc. | D- | 38/100 | — | — | -35.0% | +2.08% | $593.3M | /clym-vs-crmd → |
| IRWD Ironwood Pharmaceuticals Inc. (Class A) | C+ | 69/100 | 24.9x | — | 85.0% | +0.28% | $598.2M | /irwd-vs-crmd → |
| ACRS Aclaris Therapeutics Inc. | E | 31/100 | — | 73.3% | -35.0% | +0.76% | $587.3M | /acrs-vs-crmd → |
| NVCT Nuvectis Pharma Inc. | D- | 43/100 | — | — | -35.0% | +1.14% | $605.6M | /nvct-vs-crmd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001410098In its most recent audited fiscal period (FY2025, filed 2025-12-31), CorMedix Inc. (CRMD) reported GAAP revenue of $311.7M (+617.0% vs. FY2024 revenue of $43.5M ) , GAAP net income of $163.1M, operating cash flow of $175.0M, and free cash flow of $172.8M (+440.6% YoY). On the balance sheet, CRMD closed FY2025 with $826.1M in total assets against $0 in total debt (Altman Z-Score: 1.81, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $311.7M | $163.1M | $175.0M | $172.8M | $826.1M | — |
| FY2024 (FY) | 2024-12-31 | $43.5M | -$17.9M | -$50.6M | -$50.7M | $118.8M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$46.3M | -$38.4M | -$38.4M | — | — |
3. CRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, CorMedix Inc. (NASDAQ: CRMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $7.64 (-6.83% 1D, market cap $595.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, CRMD ranks #171 in composite RQD confidence.
How does CRMD compare to CLYM and IRWD in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRMD carries a Roarable C (62/100 RQD), trailing P/E of 3.7x, gross margin of 88.5%, and ROIC of 45.5%. By comparison, CLYM (Climb Bio Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $593.3M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C+ grade (69/100 RQD, P/E 24.9x, ROIC 85.0%, cap $598.2M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CRMD?
Per CRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001410098), CorMedix Inc. generated $311.7M in revenue (+617.0% YoY), $163.1M in net income, and $172.8M in free cash flow against $826.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (89% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CRMD trading relative to its 50-day, 200-day, and 52-week technical levels?
CRMD last traded at $7.64 (-6.83% on volume of 1,887,190 shares), positioning the stock -2.05% below its 50-day simple moving average ($7.80) and -0.39% below its 200-day simple moving average ($7.67). Across its 52-week range of $5.63 to $13.02, CRMD sits at the 27.2% percentile with a 14-day RSI of 25.3 (OVERSOLD (<32)) and an implied next-earnings move of ±11.4% ($6.77 to $8.51).
CRMD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CRMD stock moving today?
Why CRMD Stock dropped -6.83% Today — RQD Quant Desk Flash. Solid 89% profit margin (46% return on capital), mixed timing at 4x P/E—hold if owned, no rush to chase.